NCT06420973View on ClinicalTrials.gov

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

May 17, 2027

Study Completion Date

September 17, 2027

Conditions
Ovarian CarcinomaFallopian Tube CarcinomaPrimary Peritoneal Carcinoma
Interventions
DRUG

RC48+carboplatin±bevacizumab

RC48 (2.5mg/kg iv on d1 , every 21d for 6 cycles) + Carboplatin (AUC5 iv on d1 every 21d for 6 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for 6 cycles) for treatment followed by RC48 (2.5mg/kg iv on d1 , every 21d for 8 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for progress ) maintenance therapy.

Trial Locations (1)

100142

RECRUITING

Hong Zheng, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER